1. Home
  2. EFSI vs IMUX Comparison

EFSI vs IMUX Comparison

Compare EFSI & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Financial Services Inc

EFSI

Eagle Financial Services Inc

HOLD

Current Price

$41.14

Market Cap

225.9M

Sector

Finance

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$13.78

Market Cap

209.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EFSI
IMUX
Founded
1881
2016
Country
United States
United States
Employees
253
66
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
225.9M
209.2M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
EFSI
IMUX
Price
$41.14
$13.78
Analyst Decision
Buy
Strong Buy
Analyst Count
4
6
Target Price
$41.50
$36.00
AVG Volume (30 Days)
70.3K
133.8K
Earning Date
04-23-2026
05-14-2026
Dividend Yield
3.26%
N/A
EPS Growth
N/A
38.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$31.93
N/A
Revenue Next Year
$4.38
N/A
P/E Ratio
$24.38
N/A
Revenue Growth
N/A
N/A
52 Week Low
$31.44
$0.51
52 Week High
$44.00
$15.84

Technical Indicators

Market Signals
Indicator
EFSI
IMUX
Relative Strength Index (RSI) 52.39 36.95
Support Level $41.10 $11.21
Resistance Level $43.48 $13.30
Average True Range (ATR) 1.22 0.90
MACD -0.09 -0.31
Stochastic Oscillator 50.41 10.38

Price Performance

Historical Comparison
EFSI
IMUX

About EFSI Eagle Financial Services Inc

Eagle Financial Services Inc is a locally owned and managed financial institution. It offers retail and commercial banking services, including demand, savings and time deposits and consumer, mortgage, and commercial loans. It also offers telephone banking, internet banking, and mobile banking to its customers. The Company has three reportable operating segments, Community Banking, Marine Lending and Wealth Management. It generates a majority of its revenue from the Community Banking segment.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: